Pancreatic Cancer Research

ResearcherLinköping UniversityActive in the last 2 years

Hakon Blomstrand

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9845-1410; OpenAlex author ID A5062872543. Sources: OpenAlex.

Their work

Papers
12 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 3 papers

Papers 12

  1. Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer. First author DOI 10.1245/s10434-026-20191-5↗
  2. ASO Visual Abstract: Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer. First author DOI 10.1245/s10434-026-20304-0↗
  3. ASO Author Reflections: Understanding the Prognostic Role of Claudin 18.2 in Resected Pancreatic Cancer. First author DOI 10.1245/s10434-026-20312-0↗
  4. PCD-CT Versus EID-CT in Imaging of Pancreatic Ductal Adenocarcinoma: A Prospective Comparative Pilot Study. Co-author DOI 10.21873/anticanres.17536↗
  5. Intratumoural expression of dihydropyrimidine dehydrogenase is an independent prognostic factor in resected pancreatic ductal adenocarcinoma treated with adjuv… Co-author DOI 10.3892/ol.2024.14845↗
  6. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer. Co-author DOI 10.1038/s41591-024-03075-7↗
  7. Impact of resection margins and para-aortic lymph node metastases on recurrence patterns and prognosis in resectable pancreatic cancer - a long-term population… Co-author DOI 10.1016/j.hpb.2023.08.006↗
  8. Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer. Co-author DOI 10.5306/wjco.v12.i9.787↗
  9. Complete Radiologic Response of Metastatic Pancreatic Ductal Adenocarcinoma to Microwave Ablation Combined with Second-Line Palliative Chemotherapy. Co-author DOI 10.1155/2020/4138215↗
  10. Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel. Co-author DOI 10.1186/s12885-020-07426-8↗
  11. Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.01176↗
  12. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. Co-author DOI 10.1186/s12885-018-5244-2↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nils O. Elander · 10 shared papers, 2019–2026 · strength 2.09
  2. Bergþór Björnsson · 5 shared papers, 2020–2025 · strength 1.03
  3. Oskar Franklin · 4 shared papers, 2025–2026 · strength 1.00
  4. Malin Sund · 4 shared papers, 2025–2026 · strength 1.00
  5. Daniel Öhlund · 4 shared papers, 2025–2026 · strength 1.00
  6. Jun Yoshino · 3 shared papers, 2026 · strength 0.77
  7. Asif Halimi · 3 shared papers, 2026 · strength 0.77
  8. Hanna E. Seppänen · 3 shared papers, 2026 · strength 0.77
  9. Caj H. Haglund · 3 shared papers, 2026 · strength 0.77
  10. Ella Kesti · 3 shared papers, 2026 · strength 0.77
  11. Emma Gränsmark · 2 shared papers, 2020 · strength 0.27
  12. Mischa Woisetschläger · 1 shared paper, 2025 · strength 0.27
  13. Atul Batra · 1 shared paper, 2021 · strength 0.19
  14. Winson Y. Cheung · 1 shared paper, 2021 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.